Europe
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Daiichi Sankyo’s and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has become the first HER2-directed medication approved to treat gastric cancer in the U.S. in 10 years.
Thermo Fisher Scientific announced the completion of Henogen SA, Groupe Novasep SAS’s viral vector manufacturing business in Belgium. The deal was for €725 million in cash.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
PRESS RELEASES